P2RY1

P2Y purinoceptor 1 · P47900 · P2RY1 on Sugi Atlas →

44,501 patent compounds predicted against P2RY1, 27,615 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL169937	0.75	20/20
Diflufenican (SCHEMBL22023)	0.77	14/20
SCHEMBL400451	0.50	14/20
SCHEMBL135002	0.72	12/20
Adenosine Triphosphate (SCHEMBL28357)	0.78	11/20
Adenosine Triphosphate (SCHEMBL574960)	0.83	10/20
Adenosine Phosphate (SCHEMBL145417)	0.83	9/20
Adenosine Phosphate (SCHEMBL353218)	0.83	9/20
Adenosine Triphosphate (SCHEMBL28359)	0.78	9/20
SCHEMBL309060	0.71	9/20
SCHEMBL626000	0.70	9/20
SCHEMBL543337	0.83	8/20
Adenosine Triphosphate (SCHEMBL193646)	0.80	8/20
SCHEMBL625828	0.79	8/20
Adenosine Triphosphate (SCHEMBL398031)	0.79	8/20
Fludarabine Phosphate (SCHEMBL3511)	0.73	8/20
Fludarabine Phosphate (SCHEMBL482449)	0.73	8/20
SCHEMBL109340	0.72	8/20
Adenosine (SCHEMBL353216)	0.69	8/20
SCHEMBL316941	0.66	8/20

Clinical trials — most relevant to P2RY1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel	PHASE4	COMPLETED
Add-on Cangrelor in STEMI-triggered Cardiac Arrest	PHASE4	UNKNOWN
Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine	PHASE4	COMPLETED
Reversal of the Anti-platelet Effects of Ticagrelor	PHASE4	COMPLETED
Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH)	PHASE4	COMPLETED
The Effects of Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention	PHASE4	UNKNOWN
Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR	PHASE4	NOT_YET_RECRUITING
PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment	PHASE4	COMPLETED
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study	PHASE4	COMPLETED
Ticagrelor in Remote Ischemic Preconditioning Study	PHASE4	COMPLETED
Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.	PHASE3	WITHDRAWN
Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease	PHASE2/PHASE3	COMPLETED
Clopidogrel and Response Variability Investigation Study 2	PHASE3	COMPLETED
Trimetazidine as an Adjunct to Enhance Clopidogrel Response.	PHASE2	COMPLETED
POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy	PHASE2	RECRUITING
Study to Investigate the Effect of PBF-680 on Forced Expiratory Volume in 1 Second (FEV1) in Asthmatic Patients	PHASE2	COMPLETED
The Impact of Genotype on Pharmacokinetics and Antiplatelet Effects of Ticagrelor in Healthy Chinese	PHASE1	COMPLETED
Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects	PHASE1	COMPLETED
Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults	EARLY_PHASE1	COMPLETED
Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence	nan	COMPLETED
Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients	nan	RECRUITING
Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention	nan	COMPLETED
Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)	nan	ACTIVE_NOT_RECRUITING
BIOmarkers and PLAtelet Function Assessment in Myocardial Ischemia and Non Obstructive Coronary Arteries Study	nan	RECRUITING
Potential Effect of Acute and Chronic Caffeine Administration on Platelet Reactivity in Patient With Coronary Artery Disease on Dual Antiplatelet Therapy	nan	UNKNOWN
Functional Magnetic Resonance Imaging of ATP Cough in Chronic Cough Patients	nan	COMPLETED
Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES	nan	UNKNOWN
Downstream Molecular Signals of P2Y12 Receptors in Hyporeactive Patients Under Clopidogrel Treatment A Possible Mechanism of HOTPR(High On-Treatment Platelet Reactivity)	nan	COMPLETED
The Role of Urinary ATP in the Diagnosis, Treatment, and Follow-up of Children With Overactive Bladder	nan	COMPLETED
An Investigation Into the Mechanism of Inhalation Cough Challenge	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a P2RY1 binder may also engage these)

Protein	Name	Similarity
P59902	—	1.000	P59902 →
P48042	—	1.000	P48042 →
P49650	—	1.000	P49650 →
P49651	—	1.000	P49651 →
P34996	—	0.999	P34996 →
P49652	—	0.997	P49652 →
OXGR1	2-oxoglutarate receptor 1	0.991	landscape →
Q924T8	—	0.989	Q924T8 →
Q3U507	—	0.988	Q3U507 →
D4A7K7	—	0.988	D4A7K7 →
Q6IYF8	—	0.988	Q6IYF8 →
Q3U6B2	—	0.987	Q3U6B2 →
Q99JA4	—	0.986	Q99JA4 →
Q2NNR5	—	0.986	Q2NNR5 →
Q09QM4	—	0.985	Q09QM4 →
Q6NS65	—	0.985	Q6NS65 →
A5PLE7	—	0.985	A5PLE7 →
Q6Y1R5	—	0.984	Q6Y1R5 →
SUCNR1	Succinate receptor 1	0.984	landscape →
GPR17	Uracil nucleotide/cysteinyl leukotriene receptor	0.984	landscape →
GPR183	G-protein coupled receptor 183	0.983	landscape →
CYSLTR2	Cysteinyl leukotriene receptor 2	0.982	landscape →
P56482	—	0.982	P56482 →
O08675	—	0.981	O08675 →
Q00991	—	0.981	Q00991 →
Q9BY21	—	0.981	Q9BY21 →
GPR174	Probable G-protein coupled receptor 174	0.981	landscape →
F2R	Proteinase-activated receptor 1	0.980	landscape →
Q61038	—	0.980	Q61038 →
O54689	—	0.979	O54689 →